nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Eye disorder—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gadoversetamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Flushing—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Gadoversetamide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Gadoversetamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gadoversetamide—Asthenia—Teniposide—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Gadoversetamide—Melaena—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Gadoversetamide—Malaise—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Gadoversetamide—Pruritus—Teniposide—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gadoversetamide—Arrhythmia—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gadoversetamide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Gadoversetamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gadoversetamide—Mental disorder—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Gadoversetamide—Erythema—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Malnutrition—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Cough—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gadoversetamide—Angiopathy—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Gadoversetamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Gadoversetamide—Myalgia—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Chest pain—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gadoversetamide—Back pain—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Gadoversetamide—Discomfort—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Mental disorder—Vincristine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Gadoversetamide—Chills—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Gadoversetamide—Ecchymosis—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Gadoversetamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Gadoversetamide—Confusional state—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Vision blurred—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Gadoversetamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Tremor—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Oedema—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Gadoversetamide—Erythema—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gadoversetamide—Back pain—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Vomiting—Teniposide—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Gadoversetamide—Agitation—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Asthenia—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Rash—Teniposide—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Dermatitis—Teniposide—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Gadoversetamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Headache—Teniposide—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gadoversetamide—Pruritus—Fludarabine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Gadoversetamide—Anorexia—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadoversetamide—Agitation—Vincristine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Hypotension—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Gadoversetamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Gadoversetamide—Convulsion—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gadoversetamide—Hypertension—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Nausea—Teniposide—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Gadoversetamide—Vertigo—Vincristine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Myalgia—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Chest pain—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Gadoversetamide—Anxiety—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadoversetamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gadoversetamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Gadoversetamide—Convulsion—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Gadoversetamide—Hypertension—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Confusional state—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Gadoversetamide—Oedema—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Gadoversetamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Myalgia—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gadoversetamide—Cough—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Vomiting—Fludarabine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Gadoversetamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Rash—Fludarabine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadoversetamide—Pain—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Headache—Fludarabine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Gadoversetamide—Tachycardia—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gadoversetamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadoversetamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Oedema—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Anorexia—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadoversetamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gadoversetamide—Confusional state—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Hypotension—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Oedema—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Gadoversetamide—Nausea—Fludarabine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Gadoversetamide—Shock—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Urticaria—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Anorexia—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadoversetamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Insomnia—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gadoversetamide—Hypotension—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Somnolence—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadoversetamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Gadoversetamide—Insomnia—Vincristine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Gadoversetamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Constipation—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Pain—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Gadoversetamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadoversetamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Gadoversetamide—Fatigue—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Asthenia—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Pain—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Constipation—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Asthma—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Gadoversetamide—Pruritus—Bleomycin—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Gadoversetamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Gadoversetamide—Pain—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Constipation—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gadoversetamide—Abdominal pain—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Gadoversetamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Gadoversetamide—Dysuria—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Gadoversetamide—Abdominal pain—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Gadoversetamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Gadoversetamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Pneumonia—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadoversetamide—Vomiting—Bleomycin—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Gadoversetamide—Rash—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gadoversetamide—Asthenia—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Gadoversetamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Gadoversetamide—Haematuria—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Gadoversetamide—Epistaxis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Asthenia—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadoversetamide—Nausea—Bleomycin—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Gadoversetamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Gadoversetamide—Dizziness—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Gadoversetamide—Haemoglobin—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Gadoversetamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Haemorrhage—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Gadoversetamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Gadoversetamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Gadoversetamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Vomiting—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Dizziness—Vincristine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Rash—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Gadoversetamide—Dermatitis—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Headache—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Gadoversetamide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gadoversetamide—Eye disorder—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Tinnitus—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Gadoversetamide—Vomiting—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Rash—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Dermatitis—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadoversetamide—Headache—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Gadoversetamide—Nausea—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Angiopathy—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Gadoversetamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Rash—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Gadoversetamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000999	0.000999	CcSEcCtD
Gadoversetamide—Chills—Methotrexate—lymphatic system cancer	0.000997	0.000997	CcSEcCtD
Gadoversetamide—Headache—Mitoxantrone—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Gadoversetamide—Mental disorder—Methotrexate—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Gadoversetamide—Malnutrition—Methotrexate—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Gadoversetamide—Erythema—Methotrexate—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Gadoversetamide—Nausea—Vincristine—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Gadoversetamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Gadoversetamide—Nausea—Mitoxantrone—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Gadoversetamide—Back pain—Methotrexate—lymphatic system cancer	0.000936	0.000936	CcSEcCtD
Gadoversetamide—Vision blurred—Methotrexate—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Gadoversetamide—Malaise—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Gadoversetamide—Vertigo—Methotrexate—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Gadoversetamide—Cough—Methotrexate—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Gadoversetamide—Convulsion—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Gadoversetamide—Arthralgia—Methotrexate—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Chest pain—Methotrexate—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Myalgia—Methotrexate—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000818	0.000818	CcSEcCtD
Gadoversetamide—Discomfort—Methotrexate—lymphatic system cancer	0.000814	0.000814	CcSEcCtD
Gadoversetamide—Confusional state—Methotrexate—lymphatic system cancer	0.000796	0.000796	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
Gadoversetamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000775	0.000775	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000773	0.000773	CcSEcCtD
Gadoversetamide—Skin disorder—Methotrexate—lymphatic system cancer	0.000767	0.000767	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000764	0.000764	CcSEcCtD
Gadoversetamide—Anorexia—Methotrexate—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Gadoversetamide—Hypotension—Methotrexate—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00072	0.00072	CcSEcCtD
Gadoversetamide—Insomnia—Methotrexate—lymphatic system cancer	0.000714	0.000714	CcSEcCtD
Gadoversetamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Gadoversetamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000704	0.000704	CcSEcCtD
Gadoversetamide—Somnolence—Methotrexate—lymphatic system cancer	0.000702	0.000702	CcSEcCtD
Gadoversetamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000695	0.000695	CcSEcCtD
Gadoversetamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000682	0.000682	CcSEcCtD
Gadoversetamide—Fatigue—Methotrexate—lymphatic system cancer	0.000681	0.000681	CcSEcCtD
Gadoversetamide—Pain—Methotrexate—lymphatic system cancer	0.000675	0.000675	CcSEcCtD
Gadoversetamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000651	0.000651	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Gadoversetamide—Urticaria—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Gadoversetamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Gadoversetamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000624	0.000624	CcSEcCtD
Gadoversetamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Gadoversetamide—Asthenia—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Gadoversetamide—Pruritus—Methotrexate—lymphatic system cancer	0.000559	0.000559	CcSEcCtD
Gadoversetamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00054	0.00054	CcSEcCtD
Gadoversetamide—Dizziness—Methotrexate—lymphatic system cancer	0.000522	0.000522	CcSEcCtD
Gadoversetamide—Vomiting—Methotrexate—lymphatic system cancer	0.000502	0.000502	CcSEcCtD
Gadoversetamide—Rash—Methotrexate—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
Gadoversetamide—Headache—Methotrexate—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Gadoversetamide—Nausea—Methotrexate—lymphatic system cancer	0.000469	0.000469	CcSEcCtD
